NV-52: A novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease

Expert Opinion on Investigational Drugs

Volumn 16, Issue 8, 2007, Pages 1255-1266

  Howes, Laurence Guy ^a   James, Michael John ^b   Florin, Timothy ^c   Walker, Catherine ^d,e  

^a BOND UNIVERSITY   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^d RandD/Anti infammatory and Cardiovascular Therapeutics Novogen Ltd

^e NONE   (Australia)

Author keywords

Crohn's disease; Inflammatory bowel disease; NV 52; Thromboxane synthase; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CONCANAVALIN A; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; INFLIXIMAB; LYMPHOPREP; MERCAPTOPURINE; MESALAZINE; NV 52; ONO NT 126; PHORBOL MYRISTATE; PLACEBO; PROSTAGLANDIN E1; PROSTAGLANDIN E2; RIDOGREL; THROMBOXANE A2; THROMBOXANE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL; CROHN DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENTERITIS; HUMAN; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; INCIDENCE; INFLAMMATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; RELAPSE; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; THROMBOXANE-A SYNTHASE;

EID: 34548202720     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.8.1255     Document Type: Review

References (60)

1. MIDDLETON E JR, KANDASWAMI C, THEOHARIDES TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacolog. Rev. (2000) 52(4):673-751.
2. HOWES JB, TRAN D, HOWES LG: Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal Type 2 diabetics. Diab. Obes. Metab. (2003) 5:325-332.
3. LAM AN, DEMASI M, JAMES MJ, HUSBAND AJ, WALKER C: Effect of red clover isoflavones on COX-2 activity in murine and human monocyte/macrophage cells. Nutr. Cancer (2004) 49(1):89-93.
4. HUANG Y, CAO S, NAGAMANI M, ANDERSON KE, GRADY JJ, LU LJ: Decreased circulating levels of tumor necrosis factor-alpha in postmenopausal women during consumption of soy-containing isoflavones. J. Clin. Endocrinol. Metab. (2005) 90(7):3956-3962.
5. VERDRENGH M, JONSSON IM, HOLMDAHL R, TARKOWSKI A: Genistein as an anti-inflammatory agent. Inflamm. Res. (2003) 52(8):341-346.
6. DUAN W, KUO IC, SELVARAJAN S, CHUA KY, BAY BH, WONG WS: Anti-inflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am. J. Resp. Crit. Care Med. (2003) 167(2):185-192.
7. HAWKEY CJ, BOUGHTON-SMITH NK, WHITTLE BJ: Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Digest. Dis. Sci. (1985) 30(12):1161-1165.
8. RAMPTON DS, COLLINS CE: Review article: thromboxanes in inflammatory bowel disease-pathogenic and therapeutic implications. Aliment. Pharmacol. Ther. (1993) 7(4):357-367.
9. 2 in nonadherent human monocytes. J. Immunol. (1997) 158(1):351-358.
10. CARTY E, MACEY M, MCCARTNEY SA, RAMPTON DS: Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment. Pharmacol. Ther. (2000) 14(6):807-817.
11. CARTY E, NICKOLS C, FEAKINS RM, RAMPTON DS: Tbromboxane synthase immunohistochemistry in inflammatory bowel disease. J. Clin. Path. (2002) 55(5):367-370.
12. 2 release by colorectal mucosa in inflammatory bowel disease. Aliment. Pbarmacol. Tber. (1996) 10(3):315-320.
13. TILLEY SL, COFFMAN TM, KOLLER BH: Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. (2001) 108(1):15-23.
14. PODOLSKY DK: The current future understanding of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. (2002) 16(6):933-943.
15. JEWELL DP: Ulcerative colitis. In: Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia, USA (1998):1735.
16. BAMIAS G, NYCE MR, DE LA RUE SA, COMINELLI F: New concepts in the pathophysiology of inflammatory bowel disease. Ann. Intern. Med. (2005) 143(12):895-904.
17. DUBUQUOY L, ROUSSEAUX C, THURU X et al.: PPAR-γ as a new therapeutic target in inflammatory bowel diseases. Gut (2006) 55(9):1341-1349.
18. DESREUMAUX P, GHOSH S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment. Pharmacol. Ther. (2006) 24(Suppl. 1):2-9.
19. SUBRAMANIAN S, CAMPBELL BJ, RHODES JM: Bacteria in the pathogenesis of inflammatory bowel disease. Curr. Opin. Infect. Dis. (2006) 19(5):475-484.
20. VILASECA J, SALAS A, GUARNER F, RODRIGUEZ R, MALAGELADA JR: Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology (1990) 98(2):269-277.
21. ALLGAYER H, DESCHRYVER K, STENSON WF: Treatment with 16,16′-dimethyl prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology (1989) 96(5 Part 1):1290-1300.
22. WALLACE JL, KEENAN CM, GALE D, SHOUPE TS: Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology (1992) 102(1):18-27.
23. TAKEUCHI K, SMALE S, PREMCHAND P et al.: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. (2006) 4(2):196-202.
24. GURUDU S, FIOCCHI C, KATZ JA: Inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. (2002) 16(1):77-90.
25. SIEGEL CA, HUR C, KORZENIK JR, GAZELLE GS, SANDS BE: Risks and benefits of infliximab for the treatment of Crohn's disease. Clin. Gastroenterol. Hepatol. (2006) 4(8):1017-1024; 976.
26. CARTY E, RAMPTON DS: Evaluation of new therapies for inflammatory bowel disease. Br. J. Clin. Pharmacol. (2003) 56(4):351-361.
27. 2 receptor antagonist in an animal model of inflammatory bowel disease. Digestion (1997) 58(5):476-478.
28. TOZAKI H, FUJITA T, ODORIBA T et al.: Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. Life Sci. (1999) 64(13):1155-1162.
29. AUWERDA JJ, ZIJLSTRA FJ, TAK CJ, VAN DEN INGH HF, WILSON JH, OUWENDIJK RJ: Ridogrel enemas in distal ulcerative colitis. Eur J. Gastroenterol. Hepatol. (2001) 13(4):397-400.
30. CARTY E, RAMPTON DS, SCHNEIDER H, RUTGEERTS R WRIGHT JP: Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Aliment. Pharmacol. Ther. (2001) 15(9):1323-1329,
31. TYTGAT GN, VAN NUETEN L, VAN DE VELDE I, JOSLYN A, HANAUER SB: Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment. Pharmacol. Ther. (2002) 16(1):87-99.
32. 2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J. Immunol. (2000) 165(3):1605-1611.
33. DEMASI M, CAUGHEY GE, JAMES MJ, CLELAND LG: Assay of cyclooxygenase-1 and 2 in human monocytes. Inflamm. Res. (2000) 49(12):737-743.
34. 2. Biochem. Biophys. Res. Comm. (1986) 137(1):404-410.
35. OKAYASU I, HATAKEYAMA S, YAMADA M, OHKUSA T, INAGAKI Y, NAKAYA R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 98(3):694-702.
36. TYTGAT KM, VAN DER WAL JW, EINERHAND AW, BULLER HA, DEKKER J: Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem. Biophys. Res. Commun. (1996) 224:397-405.
37. VAN KLINKEN BJ, VAN DER WAL JW, EINERHAND AW, BULLER HA, DEKKER J: Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut (1999) 44:387-393.
38. CORFIELD AP, MYERSCOUGH N, BRADFIELD N et al.: Colonic mucins in ulcerative colitis: evidence for loss of sulfation. Glycoconj. J. (1996) 13:809-822.
39. HANSKI C, BORN M, FOSS HD et al.: Defective post-transcriptional processing of MUC2 mucin in ulcerative colitis and in Crohn's disease increases detectability of the MUC2 protein core. J. Pathol. (1999) 188:304-311.
40. PODOLSKY DK, ISSELBACHER KJ: Composition of human colonic mucin. selective alteration in inflammatory bowel disease. J. Clin. Invest. (1983) 72:142-153.
41. DVORAK AM, OSAGE JE, MONAHAN RA, DICKERSIN GR: Crohn's disease: transmission electron microscopic studies. III. Target tissues. Proliferation of and injury to smooth muscle and the autonomic nervous system. Hum. Pathol. (1980) 11:620-634.
42. TRABUCCHI E, MUKENGE S, BARATTI C, COLOMBO R, FREGONI F, MONTORSI W: Differential diagnosis of Crohn's disease of the colon from ulcerative colitis: ultrastructure study with the scanning electron microscope. Int. J. Tissue React. (1986) 8:79-84.
43. SCHULTSZ C, BERG FV, KATE F, TYTGAT G, DANKERT J: The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology (1999) 117:1089-1097.
44. MACPHERSON A, UHRT, Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science (2004) 303:1662-1665.
45. MACPHERSON A, HUNZIKER L, MCCOY K, LAMARRE A: Review IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect. (2001) 3:1021-1035.
46. DARFEUILLE-MICHAUD A, BOUDEAU J, BULOIS P et al.: High prevalence of adherent-invasive Escherichia coli associated with deal mucosa in Crohn's disease. Gastroenterology (2004) 127:412-421.
47. MARTIN H, CAMPBELL B, HART C et al.: Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology (2004) 127:80-93.
48. RYAN P, KELLY R, LEE G et al.: Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am. J. Gastroenterol. (2004) 99:1539-1543.
49. DOTAN I, RACHMILEWITZ D: Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr. Opin. Gastroenterol. (2005) 21:426-430.
50. COLLADO M, JALONEN L, MERILUOTO J, SALMINEN S: Protection mechanism of probioric combination against human pathogens: in vitro adhesion to human intestinal mucus. Asia Pac. J. Clin. Nutr. (2006) 15:570-575.
51. ANGELIS MD, RIZZELLO C, FASANO A et al.: VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue. Biochim. Biophys. Acta (2006) 1762:80-93.
52. RIOUX KP, FEDORAK RN: Probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. (2006) 40(3):260-263.
53. WEINSTOCK JV: Helminths and mucosal immune modulation. Ann. NY Acad. Sci. (2006) 1072:356-364.
54. VAN ASSCHE G, VERMEIRE S, RUTGEERTS P: Medical treatment of inflammatory bowel diseases. Curr. Opin. Gastroenterol. (2005) 21(4):443-447.
55. DE LA RUE SA, BICKSTON SJ: Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gastroenterol. (2006) 22(4):365-369.
56. TAKAZOE M, TANAKA T. KONDO K, ICHIMORI T, SHINODA T: The present status and the recent development of the treatment for inflammatory bowel diseases: desirable effect of extracorporeal immunomodulation. Therapeut. Apheresis (2002) 6(4):305-311.
57. VILASECA J, SALAS A, GUARNER F, RODRIGUEZ R, MALAGELADA JR: Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology (1990) 98(2):269-277.
58. 2 and indomethacin on leukotriene B4 and inflammation in rabbit colitis. Prostaglandins (1988) 36(4):565-577.
59. OKETANI K, INOUE T, MURAKAMI M: Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide. Eur. J. Pharmacol. (2001) 427(2):159-166.
60. FRETLAND DJ, WIDOMSKI DL, ANGLIN CP et al.: Mucosal protective activity of prostaglandin analogs in rodent colonic inflammation. Inflammation (1992) 16(6):623-629.